Britain and America have established a significant trade agreement that will keep zero import taxes on UK pharmaceutical products being sold in the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the public health system. This move ensures that duties on these key exports will be held at zero for a duration of the next three years.
This development comes after recent statements to dramatically increase tariffs on branded pharmaceutical imports, with increases mentioned up to one hundred percent.
"This arrangement between the UK strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Impact
Pharmaceuticals represent one of the Britain's largest goods shipped to the US, which is clearly the primary market for large UK drugmakers.
Statistics indicate that in the 12 months to the end of last September, the UK sold pharmaceutical products valued at £11.1bn to the US. This value made up 17.4% of all goods exports in that timeframe.
"This guarantee protects jobs, increases capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," a minister stated.
Key NHS Changes
The pact includes several notable pledges from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must refund to the NHS to control costs will be restricted at 15%. Last year, rebates topped twenty percent.
Industry Background
The deal takes place against a protracted dispute between the drug companies and the ministers over spending levels and NHS adoption.
This friction were intensified by arguments that American patients were charged significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the past decade.
